

02/07/02
JC928 U.S. PTO

02/11/02

A

Please type a plus sign (+) inside this box ☐ +
Approved for use through 10/31/2002 OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	44.US4.DIV
First Inventor	Lydie BOUGUELERET
Title	A Nucleic Acid Encoding a Retinoblastoma Binding Protein (RBP07) and Polymorphic Markers Associated with Said Nucleic Acid
Express Mail Label No.	EV 016276670 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

- ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
- ☐ Applicant claims small entity status.
See 37 CFR 1.27.
- ☒ Specification [Total Pages 105]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
- ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 2]
- Oath or Declaration [Total Pages 1]
 - ☐ Newly executed (original or copy)
 - ☒ Copy from a prior application (37 CFR 1.63 (d))
(for continuation/divisional with Box 18 completed)
 - ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)
- ☒ Application Data Sheet. See 37 CFR 1.76

- ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
- Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - ☐ Computer Readable Form (CRF)
 - Specification Sequence Listing on:
 - ☐ CD-ROM or CD-R (2 copies); or
 - ☒ paper
 - ☒ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- ☐ Assignment Papers (cover sheet & document(s))
- ☒ 37 CFR 3.73(b) Statement (when there is an assignee) ☒ Power of Attorney
- ☐ English Translation Document (if applicable)
- ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
- ☒ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
- ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
- ☐ Other:

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment or in an Application Data Sheet under 37 CFR 1.76:

<input type="checkbox"/> Continuation	<input checked="" type="checkbox"/> Divisional	<input type="checkbox"/> Continuation-in-part (CIP)	of prior application No	09	/	345,882
Prior application information:			Examiner	K. Katchereh	Group	Art Unit. 1656

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label	000027206	or	<input checked="" type="checkbox"/> Correspondence address below
(Insert Customer No. or Attach bar code label here)			
Name	John Lucas, Ph.D., J.D.		
Address	GENSET CORPORATION 10665 Sorrento Valley Road		
City	San Diego	State	CA
Country	U.S.A.	Telephone	858/597-2600
		Fax	858/597-2601

Name (Print/Type)	John Lucas, Ph.D., J.D.	Registration No. (Attorney/Agent)	43,373
Signature		Date	2/7/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

10/07/1179
02/07/02
The PTO did not receive the following listed item(s) Specification 105 pages

02/07/02
JC928 U.S. P.T.O.

PTO/SB/17 (10-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$ 740.00

Complete if Known

Application Number	
Filing Date	February 7, 2002
First Named Inventor	Lydie Bougueleret
Examiner Name	K. Katcheres
Group Art Unit	1656
Attorney Docket No.	44.US4 DIV

METHOD OF PAYMENT

1. ☐ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number: 50-1181
Deposit Account Name: Genset Corporation

- ☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17
☐ Applicant claims small entity status. See 37 CFR 1.27

2. ☒ Payment Enclosed:

☒ Check ☐ Credit card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
101	740	201	370	Utility filing fee	740
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	

SUBTOTAL (1) (\$ 740.00

2. EXTRA CLAIM FEES

Total Claims: 3
Independent Claims: 1
Multiple Dependent Claims: 0
Extra Claims: 20** = 0
Fee from below: 18 = 0
Fee Paid: 0

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 0.00

*or number previously paid, if greater, For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0.00

SUBMITTED BY

Express Mail Label No. EV 016276670 US

Complete (if applicable)

Name (Print/Type)

John Lucas, Ph.D., J.D.

Registration No.
(Attorney/Agent)

43,373

Telephone

(858) 597-2600

Signature

Date

2/6/02

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JC928 U.S. PTO
02/07/02



G

E

N

S

E

T

Direct Dial: (858) 597-2610
E-Mail: john.lucas@genxy.com

February 7, 2002

Express Mail Label No. EV 016276670 US

Assistant Commissioner for Patents
Box: Patent Application
Washington, D.C. 20231

RE: U.S. Divisional Patent Application
For: A NUCLEIC ACID ENCODING A RETINOBLASTOMA BINDING PROTEIN (RBP-7) AND
POLYMORPHIC MARKERS ASSOCIATED WITH SAID NUCLEIC ACID
Inventor(s): Lydie BOUGUELERET
Our Ref.: 44.US4.DIV

Dear Sir:

Enclosed please find the above-identified utility patent application for filing with the United States Patent and Trademark Office. This application is a divisional of U.S. Patent Application Serial No. 09/345,882, filed June 30, 1999 which claims priority on U.S. Provisional Application Serial No. 60/091,315, filed June 30, 1998; and U.S. Provisional Application Serial No. 60/60/111,909, filed December 10, 1998. The following documents are transmitted herewith:

	<u>Quantity</u>
1) Specification, Claims and Abstract	105 pages
2) Application Data Sheet	3 pages
3) Preliminary Amendment	3 pages
4) Utility Patent Application Transmittal, Fee Transmittal for FY 2002, Patent Application Fee Determination Record	3 sheets
5) Power of Attorney or Authorization of Agent; Statement Under 37 CFR 3.73(b)	2 pages
6) Our check in the amount of \$740.00 for the filing fee	
7) Paper copy of Sequence Listing	126 pages
8) Sequence Listing Verification Statement Under 1.821	1 page
9) Return Receipt Postcard	2 pages
10) Drawings	

The Commissioner is hereby authorized to charge any additional fees, or credit any overpayment in the processing of these documents to our Deposit Account No. 50-1181.

Very truly yours,

GENSET CORPORATION

John Lucas, Ph.D., J.D.
Reg. No. 43,373

JL/DD/cmm
Enclosures
cc: Helene Sarraesca (w/encls.)

Certificate of Mailing under 37 CFR 1.10

Express Mail Label No.: EV 016276670 US Date of Deposit: February 7, 2002
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, on the Date of Deposit shown above, postage prepaid and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Signature

Deno P. Dialynas

Typed or Printed Name of Person Signing Certificate

Our Ref. No. 44.US4.DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Divisional Application of:)
Applicant : Lydie Bougueleret) Grp./A.U. : 1656
Appl. No. :) Examiner : K. Katcheres
Filed : February 7, 2002)
Parent Application:)
Serial No. : 09/345,882)
Filed : June 30, 1999)
Title : A NUCLEIC ACID ENCODING A)
RETINOBLASTOMA BINDING PROTEIN)
(RBP-7) AND POLYMORPHIC)
MARKERS ASSOCIATED WITH SAID)
NUCLEIC ACID.)

SUBMISSION OF SEQUENCE LISTING AND STATEMENT UNDER 1.821

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The paper copy of the Sequence Listing in this application is identical to the computer readable copy of the Sequence Listing filed in application Serial Number 09/345,882, filed June 30, 1999.

In accordance with 37 CFR 1.821(e), please use the computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the instant application. A paper copy of the Sequence Listing was included in the


originally-filed specification of the instant application. The undersigned hereby certifies that the paper and computer readable copies contain the same information.

The Commissioner is hereby authorized to credit any overpayment or charge any additional fees under 37 C.F.R. §§ 1.16 or 1.17 as required by this paper to our Deposit Account No. 50-1181.

Respectfully submitted,
GENSET CORPORATION

Date: 2/7, 2002

By:


John Lucas, Ph.D., J.D.
Registration No. 43,373

10665 Sorrento Valley Road
San Diego, CA 92121-1609
Telephone: (858) 597-2600
Facsimile: (858) 597-2601


e-mail:
john.lucas@genxy.com

Certificate of Mailing under 37 CFR 1.10

Express Mail Label No.: EV 016276670 US

Date of Deposit: 2-7-02

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, on the Date of Deposit shown above, postage prepaid and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.


Signature

Deno P. Dialynas
Typed or Printed Name of Person Signing Certificate

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Lydie Bougueleret
Application No./Patent No.: _____ Filed/Issue Date: February 7, 2002
Entitled: A Nucleic Acid Encoding a Retinoblastoma Binding Protein (RBP-7) and Polymorphic Markers Associated with Said Nucleic Acid
GENSET, a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____ %
in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 010304, Frame 0259, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

2/7/02
Date

John Lucas, Ph.D., J.D.
Typed or printed name
[Signature]
Signature
Director, Intellectual Property
Title

Appln. No. 10/071,179
 Filed: February 7, 2002
 Page 2 of 2

Please charge any additional fees, or credit overpayment to Deposit Account No.

50-1181.

Respectfully submitted,

GENSET CORPORATION

Date: March 11, 2002

By: Deno P. Dialynas

Deno Dialynas, Ph.D.
 Reg. No. 50,711

10665 Sorrento Valley Road
 San Diego, CA 92121-1609

Telephone: (868) 597-2634
 Facsimile: (858) 597-2600
 e-mail: deno.dialynas@genxy.com

Enclosures:

- 1) Photocopy of front and back of Return Receipt Postcard
- 2) Copy of Specification, Claims, Abstract (105 pages)

Certificate of Mailing

Date of Deposit: March 11, 2002


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, on the Date of Deposit shown above, postage prepaid and in an envelope addressed to the Assistant Commissioner for Patents, Box Non Fee Amendment, Washington, D.C. 20231.

Deno P. Dialynas

Signature

Deno P. Dialynas

Typed or Printed Name of Person Signing Certificate



10071179 020702

COPY OF PAPERS
ORIGINALLY FILED

Docket No.: 44,054, DIV Patent Application.

The Patent and Trademark Office date stamp sets forth the date of receipt of:

Applicant: CYDIE BOUGUEVERET
Title: ANNUAL FEED ENCODING A RETINOBLASTOMA BINDING
PROTEINCRAB-3 POLYMORPHIC MARKERS ASSOC. W/ SAID NUCLEIC

- ☒ Transmittal Letter
☒ Application: 98 Pgs./Spec. 1 Pgs./Abstract
64 Pgs./Claims 1 Total Claims
☒ Utility: Original / Div.
☐ Provisional ☐ Design ☐ Plant
☐ National Stage Filing in U.S.
☒ Preliminary Amendment 3 Pgs (3 claims)
☒ Check(s) 740.00 (23719)
☒ Drawings 2 Sheets:
☐ Formal ☐ Informal
☐ Photographs ☐ B&W ☐ Color
☐ Information Disclosure Statement
☐ PTO 1449 Form - pages
☐ Prior Art References - No. of Ref.
- ☒ Application Data Sheet - 3 Pgs
☒ ~~Comb.~~ Decl. & Power of Attorney (copy)
☒ Signed ☐ Unsigned
☐ Assignment ☐ Record, Cvr. Sheet
☒ Statement of ~~Ownership~~ Under 3.73(b)
☐ Small Entity Statement
☐ Priority Document - pages
☐ English Translation
☒ Sequence Listing 126 Pgs
☐ Deposit Acct. Order Form (2 copies)
☒ Other: SAOS 3617 5B06
Power of Atty of Atty of Agent
SUB. of SEQ LIST & STATE UNDER 1.821
US PTO Label #EVO16276670US

Attly/Sec. J1050
Initials J1050 Matter Name 268-7 Date 2/7/2002
10/07/1179
02/07/02